北京昭衍新藥研究中心股份有限公司（「本公司」及其附屬公司統稱為「本集團」） 之董事會（「董事會」）兹通告謹定於2024年10月30日（星 期 三）舉 行 董 事 會 會 議，以 考慮及通過（其 中 包 括）本集團截至2024年9月30日止九個月之第三季度業績及 其 發 佈。 承董事會命 北京昭衍新藥研究中心股份有限公司 主 席 馮宇霞 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 董事會召開日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 中 國，北 京 2024年10月18日 於 本 公 告 日 期，本 公 司 董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 左 從 林 先 生、高 大 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2024-047 一、 回购股份的基本情况 北京昭衍新药研究中心股份有限公司（以下简称"公司"）于 2024 年 3 月 28 日召开第四届董事会第七次会议，审议通过了《昭衍新药关于以集中竞价交易方 式回购公司 A 股股份的议案》，同意公司以自有资金通过上海证券交易所交易系 统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）。回购的股份 将用于股权激励或员工持股计划，回购价格不超过 28.10 元/股，回购资金总额不 低于人民币 0.5 亿元（含），不超过人民币 1 亿元（含），回购期限自公司董事会 审议通过本次回购方案之日起 12 个月内。具体内容详见公司于 2024 年 3 月 29 日 披露的《昭衍新药关于以集中竞价交易方式回购公司 A 股股份的回购报告书》（公 告编号：2024-017）。 2024 年 6 月 20 日，公司召开 2023 年年度股东大会，审议通过了《公司 2023 年度利润分配的议案》，同意公司以实施权益分派时股权登记日扣除公司回购专用 账户上已回购股份后的总股本为基数分配利润，每 10 股派发现金红利 1.6 元（ ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2024年10月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 2. 股份分類 ...

Financial Performance - JOINN Laboratories reported a revenue of RMB 1.2 billion for the first half of 2024, representing a year-on-year increase of 25%[6]. - The company achieved a net profit of RMB 300 million, up 30% compared to the same period last year[6]. - Revenue for the first half of 2024 was RMB 849,357,000, a decrease of 16.1% compared to RMB 1,012,077,000 in the same period of 2023[12]. - Gross profit for the first half of 2024 was RMB 211,301,000, down 52.8% from RMB 447,799,000 in the first half of 2023[12]. - The company reported a net loss attributable to equity shareholders of RMB 169,742,000 for the first half of 2024, a decline of 287.3% compared to a profit of RMB 90,627,000 in the same period of 2023[12]. - The gross margin decreased to 24.9% in the first half of 2024 from 44.2% in the same period of 2023, a reduction of 19.3 percentage points[12]. - The company reported a net loss of RMB 172.2 million for the six months ended June 30, 2024, compared to a profit of RMB 89.5 million for the same period in 2023, resulting in a net profit margin of -20.3%[30]. - The company reported a total comprehensive loss for the six months ended June 30, 2024, was RMB 169,213 thousand, compared to a total comprehensive income of RMB 102,760 thousand in 2023[91]. Market Expansion and Strategy - JOINN Laboratories plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by 2025[6]. - The company is exploring potential acquisitions to enhance its capabilities in biopharmaceuticals, with a budget of RMB 500 million allocated for this purpose[6]. - The company aims to enhance its market share and international influence in the non-clinical pharmacology and toxicology evaluation business, focusing on expanding upstream and downstream capabilities[36]. - The company plans to improve service quality by establishing new technologies and methods, optimizing internal management systems, and expanding production capacity to maintain its market share in non-clinical research services[37]. Research and Development - The company is investing RMB 200 million in R&D for new drug development, focusing on oncology and rare diseases[6]. - The company is focusing on enhancing its R&D service capabilities and quality, leveraging AI and information technology to improve operational efficiency[13]. - The company aims to expand its upstream and downstream business capabilities and build a new drug discovery platform to enhance one-stop service levels[13]. - The company is continuously updating and improving its non-clinical safety evaluation system for innovative drugs, including new types of ADC and PROTAC drugs[19]. - The company has established a high-level technical team of over 40 people and set up laboratories in Suzhou and Beijing for drug quality research and testing[23]. Operational Efficiency - JOINN Laboratories aims to enhance operational efficiency, targeting a reduction in operational costs by 10% by the end of 2024[6]. - The company plans to enhance its project management capabilities and operational efficiency to ensure the smooth launch of new experimental facilities[37]. - The company will continue to improve its performance evaluation, training, and compensation systems to boost employee productivity and support overall strategic goals[38]. Facilities and Compliance - The construction of the Suzhou Zhaoyan Phase II facility, covering 20,000 square meters, has been completed in 2023 and is expected to be operational by early 2025, enhancing business throughput and performance growth[15]. - The company has successfully passed the FDA GLP inspection for its Beijing facility for the third time, demonstrating its compliance with international GLP operational management standards[17]. - The company is actively advancing the construction of the Guangzhou Zhaoyan Anping base to support strategic planning and business needs[15]. Shareholder Information - The board does not recommend the payment of an interim dividend for the six months ending June 30, 2024[42]. - As of June 30, 2024, the company has a total of 749,888,699 issued shares, including 630,893,493 A shares and 118,995,206 H shares[44]. - Major shareholder Mr. Zhou holds 74,725,981 A shares, representing approximately 11.84% of the A shares and 9.96% of the total shares[46]. Financial Position and Assets - Total assets as of June 30, 2024, were RMB 9,661,274,000, a decrease of 3.6% from RMB 10,027,159,000 at the end of 2023[12]. - Cash and cash equivalents as of June 30, 2024, were RMB 2,158.2 million, a decrease of 24.6% from RMB 2,862.9 million as of December 31, 2023[32]. - The company reported a total of RMB 1,843,164,000 in financial assets at fair value through profit or loss as of June 30, 2024, an increase of 92.5% from RMB 961,138,000 as of December 31, 2023[132]. Employee and Talent Management - The company has a professional service team of 2,585 members as of June 30, 2024, reflecting ongoing talent development initiatives[14]. - The company is actively applying for national and regional talent policies to ensure long-term stability of its talent pool[14]. - The company will actively recruit industry experts with overseas experience to strengthen its domestic team's international business capabilities[37]. Related Party Transactions - The company has significant related party transactions with entities controlled by major shareholders, including Shutaishen (Beijing) Biopharmaceutical Co., Ltd.[163]. - Revenue from services provided to Shuyishen Group decreased to RMB 10,385,000 for the six months ended June 30, 2024, down from RMB 31,542,000 for the same period in 2023, representing a decline of approximately 67.0%[166].

（於中華人民共和國註冊成立的股份有限公司） 股份代號：6127 2024 中期報告 目錄 | 釋義 | 2 | | --- | --- | | 技術詞彙 | 6 | | 公司資料 | 7 | | 財務概要 | 9 | | 主席報告 | 10 | | 管理層討論及分析 | 11 | | 企業管治及其他資料 | 26 | | 未經審核綜合損益及其他全面收益表 | 44 | | 未經審核綜合財務狀況表 | 46 | | 未經審核綜合權益變動表 | 48 | | 未經審核綜合現金流量表 | 50 | | 未經審核中期財務報告附註 | 51 | 釋義 於本報告內，除文義另有所指外，下列詞彙具有以下涵義。該等詞彙及其定義未必與任何業內標準定義相符，亦未必 可直接與其他在本公司相同行業內經營的公司所採用的同類詞彙比較。 | 「2018年購股權及 | 指 | 本公司於2018年2月27日採納及批准的購股權及受限制股份獎勵計劃，其主 | | --- | --- | --- | | 受限制股份獎勵計劃」 | | 要條款載於招股章程 | | 「2019年購股權及 | 指 | 本公司於2019年8月15日採納及批准的購股權及受限制股 ...

FF305 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 603127 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2024年9月20日 | | 628,405,814 | 2,076,314 | | 630,482,128 | | 1). 購回股份 (股份被持作庫存股份) | | | -60,000 0.01 % | 60,000 RMB | 13.512 | | | 變動日期 2024年9月24日 | | | | | | | | 於下列 ...

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京昭衍新藥研究中心股份有限公司 呈交日期： 2024年9月20日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 603127 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（ ...

公司名稱： 北京昭衍新藥研究中心股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2024年9月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 603127 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份） ...

Investment Rating - The report maintains an "Outperform" rating for Zhaoyan New Drug (603127 SH) [2][4] Core Views - Short-term performance pressure in H1 2024, with signs of recovery in Q2 [2][5] - Revenue in H1 2024 was RMB 849 million (-16 1%), with net profit attributable to shareholders of -RMB 170 million (-287 3%) [2] - Q2 revenue was RMB 525 million (-18 4%), a 61 5% increase from Q1, with net profit turning positive at RMB 102 million [2][5] - The company's core non-clinical business maintains a leading industry position, with continuous innovation in technology platforms [2][11] - Clinical services show strong growth momentum, particularly in early-stage clinical research and gene therapy [2][12] Financial Performance - H1 2024 gross margin was 30 4% (-14 0pp), and net margin was -20 3% (-29 1pp) [9] - Operating expenses ratio increased to 18 4% (+3 8pp) in H1 2024 [9] - The company's order backlog was RMB 2 9 billion (-25 1%) as of H1 2024, with new orders of RMB 900 million (-30 8%) [2][10] - Q2 new orders were RMB 500 million, a 20% increase from Q1 [2][10] Business Development - The company's Beijing and Suzhou facilities passed FDA GLP inspections for the fifth time, enhancing quality systems [11] - Expanded disease models and drug evaluation technologies in ophthalmology, otology, and CNS fields [11] - Strengthened analytical testing platforms for small and large molecule drugs [11] - Clinical CRO services demonstrated advantages in Phase I and IIT studies, reducing client R&D costs [12] - Clinical testing services showed growth, particularly in gene therapy, supporting multiple innovative drugs in critical clinical stages [12] Profit Forecast - Revenue for 2024/2025/2026 is expected to be RMB 2 042/2 268/2 522 million, with a YoY growth of -14 1%/+11 1%/+11 2% [13][16] - Net profit for 2024/2025/2026 is expected to be RMB 91/300/335 million, with a YoY growth of -77 1%/+229 7%/+11 6% [13][16] - Gross margin for 2024/2025/2026 is forecasted at 27 8%/28 7%/29 6%, lower than 2023 levels [13][16] Valuation Metrics - PE ratios for 2024/2025/2026 are 113 8x/34 5x/30 9x [3][16] - ROE for 2024/2025/2026 is expected to be 1 1%/3 5%/3 8% [3][16] - EV/EBITDA for 2024/2025/2026 is 53 2x/39 3x/32 4x [3][16]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 有關生仝智能及熠昭（北 京）醫藥的資料 生仝智能剩餘約18.43%股 份 由 以 下 人 士 最 終 擁 有：(a)約9.54%預留給生仝智能 的 員 工 購 股 權 計 劃；(b)約0.2%由馮宇靜女士（馮 女 士 的 親 戚）擁 有；及(c)約8.69% 由八名個人（均 為 獨 立 第 三 方，且 彼 等 各 自 持 有 的 生 仝 智 能 股 份 均 少 於5%）擁 有。 茲提述北京昭衍新藥研究中心股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱 為「本集團」）日期為2024年8月30日的公告（「該公告」），內 容 有 關2024年北京昭衍 生 ...